Presenter – Dr Daniel Tillett – Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene. Bisantrene is a potent inhibitor of the Fat mass and obesity-associated (FTO) protein.
Views: 630
Presenter – Dr Daniel Tillett – Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene. Bisantrene is a potent inhibitor of the Fat mass and obesity-associated (FTO) protein.